GSK’s Q3 sales were up 11% yoy (all growth figures at CER unless specified) to £6.1bn (+5% at pro-forma), with outperformance in HIV (+65%), Vaccines (+32%; +13% at pro-forma) and Consumer Healthcare (+55%; +7% at pro-forma), being negated to some extent by the on-going weakness in the ex-HIV pharma business (-15%; -7% at pro-forma). Core operating profit was down 5% to £1.7bn (flat at pro-forma), reflecting asset swap transactions with Novartis (disposal of high-margin onco
28 Dec 2015
HIV continues to drive growth as R&D delivers mixed results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
HIV continues to drive growth as R&D delivers mixed results
GSK plc (GSK:LON) | 1,709 0 0.0% | Mkt Cap: 70,819m
- Published:
28 Dec 2015 -
Author:
Kamla Singh - Pages:
GSK’s Q3 sales were up 11% yoy (all growth figures at CER unless specified) to £6.1bn (+5% at pro-forma), with outperformance in HIV (+65%), Vaccines (+32%; +13% at pro-forma) and Consumer Healthcare (+55%; +7% at pro-forma), being negated to some extent by the on-going weakness in the ex-HIV pharma business (-15%; -7% at pro-forma). Core operating profit was down 5% to £1.7bn (flat at pro-forma), reflecting asset swap transactions with Novartis (disposal of high-margin onco